Spots Global Cancer Trial Database for first line
Every month we try and update this database with for first line cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma | NCT03797170 | Diffuse Large B... | Gut microbiota ... | 18 Years - | University of Bologna | |
| IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | NCT01265901 | Metastatic Rena... | Sunitinib GM-CSF Cyclophosphamid... IMA901 | 18 Years - | Immatics Biotechnologies GmbH | |
| Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer | NCT01583322 | Ovarian Cancer | vargatef placebo | 18 Years - | ARCAGY/ GINECO GROUP | |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | NCT01844986 | Newly Diagnosed Advanced Ovaria... FIGO Stage III-... BRCA Mutation Complete Respon... Partial Respons... First Line Plat... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| Erbitux MEtastatic Colorectal Cancer Strategy Study | NCT02484833 | Antineoplastic ... | Cetuximab FOLFIRI | 18 Years - | Catholic University of the Sacred Heart | |
| An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. | NCT04395989 | TNBC - Triple-N... | A1: Pyrotinib w... A2: nab-paclita... B1: everolimus ... B2: nab-paclita... C1: PD-1 with n... C2: nab-paclita... D1: VEGFR and n... D2: nab-paclita... E1: everolimus ... E2: nab-paclita... | 18 Years - 70 Years | Fudan University | |
| Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC | NCT04797806 | Non Small Cell ... | Anlotinib Icotinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT02412371 | Non-small Cell ... | Paclitaxel Placebo for Vel... Carboplatin Veliparib Radiotherapy | 18 Years - | AbbVie | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | NCT00514475 | Mantle Cell Lym... | 90Y-ibritumomab... | 18 Years - 65 Years | Oslo University Hospital | |
| A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | NCT05918133 | TNBC | PM8002 nab-paclitaxel | 18 Years - 75 Years | Biotheus Inc. | |
| A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) | NCT04317599 | BRAF V600E Muta... Metastatic Colo... | Non Interventio... | 18 Years - | Pierre Fabre Medicament | |
| An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. | NCT04395989 | TNBC - Triple-N... | A1: Pyrotinib w... A2: nab-paclita... B1: everolimus ... B2: nab-paclita... C1: PD-1 with n... C2: nab-paclita... D1: VEGFR and n... D2: nab-paclita... E1: everolimus ... E2: nab-paclita... | 18 Years - 70 Years | Fudan University | |
| Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | NCT02305758 | Untreated Metas... | Veliparib Placebo Modified FOLFIR... FOLFIRI Bevacizumab Fluorouracil in... | 18 Years - 99 Years | AbbVie | |
| Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer | NCT01526499 | Breast Cancer | Docetaxel and C... Docetaxel (T) | 18 Years - 70 Years | Fudan University | |
| Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma | NCT00901901 | Carcinoma, Hepa... | Sorafenib (Nexa... Erlotinib (Tarc... Placebo | 18 Years - | Bayer | |
| The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial | NCT03402048 | Stage IV, NSCLC Lung Neoplasms Bronchial Neopl... Carcinoma, Bron... Lung Diseases Neoplasms Respiratory Tra... Respiratory Tra... Thoracic Neopla... | Carboplatin Gemcitabine Pemetrexed Docetaxel Vinorelbine | 70 Years - | University of Turin, Italy | |
| Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE) | NCT03043950 | Metastatic Colo... RAS Wild-type | Panitumumab | 18 Years - | iOMEDICO AG | |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | NCT04956640 | Carcinoma, Non-... Colorectal Neop... Endometrial Neo... Ovarian Neoplas... Pancreatic Neop... Biliary Tract N... | LY3537982 Pembrolizumab Cetuximab Pemetrexed Cisplatin Carboplatin | 18 Years - | Eli Lilly and Company | |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | NCT05712356 | Cholangiocarcin... Gallbladder Can... Gallbladder Car... Intrahepatic Ch... Extrahepatic Ch... Bile Duct Cance... Gall Bladder Ca... Gall Bladder Ca... | LSTA1 Durvalumab Cisplatin Gemcitabine FOLFOX regimen Placebo | 18 Years - | Lisata Therapeutics, Inc. | |
| Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients. | NCT04614493 | Initial Radiolo... Initial Radiolo... Eligible for th... | SonoCloud-9 (SC... Temozolomide ac... | 18 Years - 70 Years | Assistance Publique - Hôpitaux de Paris | |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | NCT01844986 | Newly Diagnosed Advanced Ovaria... FIGO Stage III-... BRCA Mutation Complete Respon... Partial Respons... First Line Plat... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | NCT01265901 | Metastatic Rena... | Sunitinib GM-CSF Cyclophosphamid... IMA901 | 18 Years - | Immatics Biotechnologies GmbH | |
| Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | NCT02305758 | Untreated Metas... | Veliparib Placebo Modified FOLFIR... FOLFIRI Bevacizumab Fluorouracil in... | 18 Years - 99 Years | AbbVie | |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | NCT04956640 | Carcinoma, Non-... Colorectal Neop... Endometrial Neo... Ovarian Neoplas... Pancreatic Neop... Biliary Tract N... | LY3537982 Pembrolizumab Cetuximab Pemetrexed Cisplatin Carboplatin | 18 Years - | Eli Lilly and Company | |
| Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE) | NCT03043950 | Metastatic Colo... RAS Wild-type | Panitumumab | 18 Years - | iOMEDICO AG | |
| Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC | NCT04686305 | Locally Advance... | T-DXd Durvalumab Cisplatin Carboplatin Pemetrexed MEDI5752 | 18 Years - | AstraZeneca | |
| Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer. | NCT01229813 | Colorectal Canc... | bevacizumab, er... bevacizumab bevacizumab low dose capeci... | 18 Years - | Lund University Hospital | |
| Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL | NCT03567876 | Lymphoma, Mantl... | Venetoclax | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Single Arm on the Tolerability of Weekly Nab-paclitaxel | NCT01702844 | Non Small Cell ... | Nab-Paclitaxel | 70 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) | NCT04317599 | BRAF V600E Muta... Metastatic Colo... | Non Interventio... | 18 Years - | Pierre Fabre Medicament | |
| Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma | NCT01405573 | Advanced Adult ... | Best Supportive... sorafenib | 18 Years - | National Cancer Institute, Naples | |
| Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer | NCT03914170 | Colorectal Canc... | Folfirinox + ce... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 | NCT01836575 | Non Small Cell ... | Pemetrexed Carboplatin | 18 Years - | Instituto Nacional de Cancer, Brazil | |
| Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer. | NCT01229813 | Colorectal Canc... | bevacizumab, er... bevacizumab bevacizumab low dose capeci... | 18 Years - | Lund University Hospital | |
| Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer | NCT02229058 | Gastric Cancer | Albumin Bound P... S-1 | 18 Years - 90 Years | Sun Yat-sen University | |
| Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer | NCT02229058 | Gastric Cancer | Albumin Bound P... S-1 | 18 Years - 90 Years | Sun Yat-sen University | |
| A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | NCT05918133 | TNBC | PM8002 nab-paclitaxel | 18 Years - 75 Years | Biotheus Inc. | |
| Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | NCT00514475 | Mantle Cell Lym... | 90Y-ibritumomab... | 18 Years - 65 Years | Oslo University Hospital | |
| Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer | NCT02254941 | Metastatic Colo... | Chemotherapy Chemotherapy pl... | 18 Years - | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy | NCT05460000 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | 3 cycles chemot... 6 cycles chemot... | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer | NCT03914170 | Colorectal Canc... | Folfirinox + ce... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 | NCT01468623 | Colorectal Canc... | Pharmacokinetic... Standard of car... | 18 Years - | Myriad Genetic Laboratories, Inc. | |
| Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line | NCT05201547 | Endometrial Can... | Carboplatin-Pac... Dostarlimab | 18 Years - | ARCAGY/ GINECO GROUP | |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | NCT04956640 | Carcinoma, Non-... Colorectal Neop... Endometrial Neo... Ovarian Neoplas... Pancreatic Neop... Biliary Tract N... | LY3537982 Pembrolizumab Cetuximab Pemetrexed Cisplatin Carboplatin | 18 Years - | Eli Lilly and Company | |
| Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | NCT00514475 | Mantle Cell Lym... | 90Y-ibritumomab... | 18 Years - 65 Years | Oslo University Hospital | |
| Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer | NCT01583322 | Ovarian Cancer | vargatef placebo | 18 Years - | ARCAGY/ GINECO GROUP | |
| Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer | NCT03914170 | Colorectal Canc... | Folfirinox + ce... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib | NCT00526669 | Neoplasms, Gast... | Lapatinib and C... | 18 Years - | GlaxoSmithKline | |
| Single Arm on the Tolerability of Weekly Nab-paclitaxel | NCT01702844 | Non Small Cell ... | Nab-Paclitaxel | 70 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC | NCT04797806 | Non Small Cell ... | Anlotinib Icotinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 | NCT01836575 | Non Small Cell ... | Pemetrexed Carboplatin | 18 Years - | Instituto Nacional de Cancer, Brazil | |
| Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma | NCT00901901 | Carcinoma, Hepa... | Sorafenib (Nexa... Erlotinib (Tarc... Placebo | 18 Years - | Bayer | |
| Erbitux MEtastatic Colorectal Cancer Strategy Study | NCT02484833 | Antineoplastic ... | Cetuximab FOLFIRI | 18 Years - | Catholic University of the Sacred Heart |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
